225. 先天性腎性尿崩症 Congenital nephrogenic diabetes insipidus Clinical trials / Disease details


臨床試験数 : 15 薬物数 : 48 - (DrugBank : 18) / 標的遺伝子数 : 31 - 標的パスウェイ数 : 65

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05190744
(ClinicalTrials.gov)
September 1, 202229/12/2021PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium AdministrationA Multi-center, Open-Label, Exploratory Study to Assess the Efficacy of PB in Decreasing the Urine Output and Increasing the Urine Osmolality in Patients With Hereditary Nephrogenic Diabetes Insipidus, Patients With Autosomal Dominant Polycystic Kidney Disease Treated With Tolvaptan, And Severely Polyuric Patients With Previous Lithium Administration (Serendipity-PB1)Autosomal Dominant Polycystic Kidney Disease;Nephrogenic Diabetes Insipidus;Acquired Nephrogenic Diabetes Insipidus;Congenital Nephrogenic Diabetes InsipidusDrug: PBMayo ClinicHopital du Sacre-Coeur de MontrealRecruiting18 YearsN/AAll20Phase 2United States
2JPRN-jRCTs031180369
12/04/201818/03/2019Tolvaptan for nephrogenic diabetes insipidusExploratory study of tolvaptan use for nephrogenic diabetes insipidus caused by mutation in vasopressin type 2 receptor - Tolvaptan use for NDI by V2R mutation Nephrogenic diabetes insipidus
Nephrogenic diabetes insipidus, polyuria;D018500
Starting tolvaptan from 60 mg and dose up to 90mg and 120mg in every 1 or 2 days.Makita NorikoNULLRecruiting>= 20age oldNot applicableBoth3Phase 1-2Japan
3JPRN-UMIN000021708
2016/04/1818/04/2016A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene.A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene. - A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene. Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene1) Administration of Tolvaptan once per day (60mg/day, 90mg/day, 120mg/day), each dose for two days.
2) Administration of Tolvaptan 120mg per day for 2 to 4 weeks in outpatient.
Department of Nephrology and Endocrinology, The University of Tokyo HospitalNULLRecruiting20years-oldNot applicableMale and Female3Not selectedJapan